NCT06509009View on ClinicalTrials.gov

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2027

Conditions
Nasopharyngeal Carcinoma by AJCC V8 Stage
Interventions
DRUG

Nimotuzumab

nimotuzumab, toripalimab, gemcitabine, cisplatin

Trial Locations (1)

1000000

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medcial Science and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER